维普中文期刊产品整合服务
489篇 您的检索式:作者名="Li JB"
    题名 作者 年代 出处 被引量
1Tumor size as a prognostic factor in patients with advanced gastric cancer in the lower third of the stomach显示文摘AIM: To explore the impact of tumor size on outcomes in patients with advanced gastric cancer in the lower third of the stomach. METHODS: We retrospectively analyzed the clinical records of 430 patients with advanced gastric cancer in the lower third of the stomach who underwent distal subtotal gastrectomy and D2 lymphadenectomy in our hospital from January 1998 to June 2004. Receiver-operating characteristic (ROC) curve analysis was used to determine the appropriate cutoff value for tumor size, which was measured as maximum tumor diameter. Based on this cutoff value, patients were divided into two groups: those with large-sized tumors (LSTs) and those with small-sized tumors (SSTs). The correlations between other clinicopathologic factors and tumor size were investigated, and the 5-year overall survival (OS) rate was compared between the two groups. Potential prognostic factors were evaluated by univariate KaplanMeier survival analysis and multivariate Cox's propor-tional hazard model analysis. The 5-year OS rates in the two groups were compared according to pT stage and pN stage. RESULTS: The 5-year OS rate in the 430 patients with advanced gastric cancer in the lower third of the stomach was 53.7%. The mean ± SD tumor size was 4.9 ± 1.9 cm, and the median tumor size was 5.0 cm. ROC analysis indicated that the sensitivity and specificity results for the appropriate tumor size cutoff value of 4.8 cm were 80.0% and 68.2%, respectively (AUC=0.795, 95%CI: 0.751-0.839, P=0.000). Using this cutoff value, 222 patients (51.6%) had LSTs (tumor size ≥ 4.8 cm) and 208 (48.4%) had SSTs (tumor size<4.8 cm). Tumor size was significantly correlated with histological type (P=0.039), Borrmann type (P=0.000), depth of tumor invasion (P=0.000), lymph node metastasis (P=0.000), tumor-nodes metastasis stage (P=0.000), mean number of metastatic lymph nodes (P=0.000) and metastatic lymph node ratio (P=0.000). Patients with LSTs had a significantly lower 5-year OS rate than those with SSTs (37.1% vs 63.3%, P=0.000). Univariate analysis showed that depth of tumor invasion (c 2=69.581, P=0.000), lymph node metastasis (c 2=138.815, P=0.000), tumor size (c 2=78.184, P=0.000) and metastatic lymph node ratio (c 2=139.034, P=0.000) were significantly associated with 5-year OS rate. Multivariate analysis revealed that depth of tumor invasion (P=0.000), lymph node metastasis (P=0.019) and tumor size (P=0.000) were independent prognostic factors. Gastric cancers were divided into 12 subgroups: pT2N0; pT2N1; pT2N2; pT2N3; pT3N0; pT3N1; pT3N2; pT3N3; pT4aN0; pT4aN1; pT4aN2; and pT4aN3. In patients with pT2-3N3 stage tumors and patients with pT4a stage tumors, 5-year OS rates were significantly lower for LSTs than for SSTs (P<0.05 each), but there were no significant differences in the 5-year OS rates in LST and SST patients with pT23N0-2 stage tumors (P > 0.05). CONCLUSION: Using a tumor size cutoff value of 4.8cm, tumor size is a prognostic factor in patients with pN3 stage or pT4a stage advanced gastric cancer located in the lower third of the stomach.Hong-Mei Wang, Chang-Ming Huang, Chao-Hui Zheng, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Jun Lu, Department of Gastric Surgery, Affiliated Union Hospital of Fujian Medical University, Fuzhou 350001, Fujian Province, China Author contributions: Wang HM and Huang CM conceived of the study, analyzed the data, and drafted the manuscript Zheng CH, Li P and Xie JW helped revise the manuscript critically for important intellectual content Wang JB, Lin JX and Lu J helped collect data and design the study and all authors read and approved the final manuscript. 2012World Journal of Gastroenterology2012,18,38:15
2中医药单病例随机对照试验报告规范(中医药CENT):CENT声明的扩展、说明与详述显示文摘背景单病例随机对照试验是评价中医药干预措施有效性和安全性较为理想和适宜的方法之一。目前已有一定数量的中医药单病例随机对照试验发表。然而,由于缺乏相应的报告规范,这些试验的报告质量普遍较差。鉴于中医药临床研究的独特性,工作组制定了单病例随机对照试验报告标准(CONSORT extension for reporting N-of-1 trials,CENT 2015)的中医药扩展版(中医药CENT),以帮助研究者报告中医药单病例试验。方法我们在提高健康研究质量和透明度协作网(Enhancing the QUAlity and Transparency Of health Research,EQUATOR)上注册了中医药CENT。中医药单病例随机对照试验报告规范的制定是一个综合过程,包括收集初始报告条目,与17名专家小组成员进行两轮科学的德尔菲共识调查,修订和形成最终报告清单。结果清单共包括6个领域的25项条目,其中的8项对CENT 2015清单条目进行了扩展和详细说明。中医药CENT清单充分考虑了中医药的诊疗特点,并详细阐释了中医药单病例随机对照试验中辨证的概念和不同的中医药干预措施。结论中医药CENT是中医临床研究的一个实用工具,可用于评价中医药单病例对照试验报告的完整性,并可指导中医药单病例对照试验的设计、实施和报告,期望此报告规范可切实提高中医药单病例试验的全面性和透明度。胡嘉元(翻译) 李江(翻译) 翟静波(翻译) 李博(翻译) 田金徽(翻译) 马彬(翻译) 杨克虎(翻译) 代敏(翻译) 田贵华(翻译) 商洪才(翻译) 张弛(回译) 段玉婷(审校) 卞兆祥(审校) Li J Hu JY Zhai JB 2021中国循证医学杂志2021,21,3:7
3A novel solid state Michael addition reaction of N-heterocyclic compounds containing active C-H bond显示文摘In this paper,a novel solid state Michael-type addition reaction of N-heterocyclic compounds containing the active-CH group was investigated.3-Methyl-l-phenyl-5-pyrazolone (MPP) and indole (In) reacted with 4-arylmethylene-3-methyl-l-phenyl-5-pyrazolone (1) hi the solid state at room temperature to give the corresponding adducts,aryl-4,4’-bis(5-hydroxy-3-methyl-l-phenyl-pyrazolyl) methane (2a-n) and l-aryl-l-(5’-hydroxy-3’-methyl-1’-phenyl-4’-pyrazolyl)-l-(3'-indolyl) methane (3a-n),respectively.This is a feasible method for preparing the compound which contains two heterocyclic groups on the same carbon.Li, XL Wang, YM Tian, B Meng, JB 1996Chinese Journal of Chemistry1996,14,5:3
4The Influence of Diabetes, Hypertension, and Hyperlipidemia on the Onset of Age-Related Macular Degeneration in North China: The Kailuan Eye Study显示文摘Objective To analyze the prevalence of dry and wet age-related macular degeneration(AMD)in patients with diabetes,hypertension and hyperlipidemia,and to analyze the risk factors for AMD.Methods A population-based cross-sectional epidemiologic study was conducted involving 14,440 individuals.We assessed the prevalence of dry and wet AMD in diabetic and non-diabetic subjects and analyzed the risk factors for AMD.Results The prevalence of wet AMD in diabetic and non-diabetic patients was 0.3%and 0.5%,respectively,and the prevalence of dry AMD was 17%and 16.4%,respectively.The prevalence of wet AMD in healthy,hypertensive,hyperlipidemic,and hypertensive/hyperlipidemic populations was 0.5%,0.3%,0.2%,and 0.7%,respectively.The prevalence of dry AMD in healthy,hypertensive,hyperlipidemic,and hypertensive/hyperlipidemic populations was 16.6%,16.2%,15.2%,and 17.2%,respectively.Age,sex,body mass index,and use of hypoglycemic drugs or lowering blood pressure drugs were corrected in the risk factor analysis of AMD.Diabetes,diabetes/hypertension,diabetes/hyperlipidemia,and diabetes/hypertension/hyperlipidemia were analyzed.None of the factors analyzed in the current study increased the risk for the onset of AMD.Conclusion There was no significant difference in the prevalence of wet and dry AMD among diabetic and non-diabetic subjects.Similarly,there was no significant difference in the prevalence of wet and dry AMD among subjects with hypertension and hyperlipidemia.Diabetes co-existing with hypertension and hyperlipidemia were not shown to be risk factors for the onset of dry AMD.ZHANG Yong Peng WANG Ya Xing ZHOU Jin Qiong WANG Qian YAN Yan Ni YANG Xuan YANG Jing Yan ZHOU Wen Jia WANG Ping SHEN Chang YANG Ming LUAN Ya Nan WANG Jin Yuan WU Shou Ling CHEN Shuo Hua WANG Hai Wei FANG Li Jian WAN Qian Qian ZHU Jing Yuan NIE Zi Han CHEN Yu Ning XIE Ying JONAS JB WEI Wen Bin 2022Biomedical and Environmental Sciences2022,35,7:2
5A novel mutation of the DSRAD gene in a Chinese family with dyschromatosis symmetrica hereditaria显示文摘Li M Jiang YX Liu JB 2004Clin and Exp Dermatol2004,29,:1
6Hepatoprotective sesquiterpeneglycosides from Sarcandra glabra 显示文摘Li Y Zhang DM Li JB 2006J Nat Prod2006,69,:1
7Interleukin 12 a key immunoregulatory cytokine in infection applications显示文摘Hamza T Barnett JB Li B 2010Int J Mol Sci2010,11,3:1
8Retention of a composite dressing for aveo- lopalatal wounds 显示文摘Li KK Mulliken JB 1995Plast Reconstr Surg1995,95,4:1
9Comparative analysis of a large dataset indicates that internal transcribed spacer(ITS)should be incorporated into the core barcode for seed plants显示文摘Li DZ Gao LM Li H Wang H Ge X J Liu JQ Chen ZD Zhou SL Chen SL Yang JB 0,,:1
10Effect of heat stress on calcium ultrastructural distribution in pepper anther显示文摘Yan CHL Wang JB Li RQ 2002Environ Exp Bot2002,48,:1
11Inflammatory markers and risk of developing type 2 diabetes in women显示文摘Hu FB Meigs JB Li TY 2004Diabetes2004,53,3:1
12Gray-scale and color flow harmonic imag ing with proteinaceous microsphers显示文摘Forsberg F Li JB Rawool NM 1995Radiology1995,,:1
13Treatment of alveolar cleft with distraction osteogenesis using tooth-micro-implant joint anchorage in an animal model显示文摘Huang DY Zhang JB Li X 2012Br J Oral Maxillofac Surg2012,50,7:1
14A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer显示文摘Li H Stampfer MJ Hollis JB 2007PLoS Med2007,4,3:1
15Effects of tillage and residue management on soil nematode communities in North China显示文摘Zhang XK Li Q Zhu AN Liang W J Zhang JB Steinberger Y 2012Ecological Indicators2012,12,1:1
16Serum retinol-binding protein 4 levels in patients with diabetic retinopathy显示文摘Li ZZ Lu XZ Liu JB 2010The Journal of International Medical Research2010,38,1:1
17Drent ML (2005) Differential effect sizes of growth hormone replacement on quality of life,wellbeing and health status in growth hormone deficient patients:a metaanalysis显示文摘Deijen JB Arwert LI Witlox J 2005Health Quai Life Outcomes2005,3,:1
18Disruption of the ICOS-B7RP-1 costimulatory pathway leads to enhanced hepatic immunopathology and increased gamma interferon production by CD4 T cells in mufine schistosomiasis 显示文摘Rutitzky LI Ozkaynak E Rottman JB 2003Infect Immun2003,71,7:1
19The gene expression fingerprint of human heart failure显示文摘Tan FL Moravec CS Li JB 2002PNAS2002,99,11:1
20Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice 显示文摘Li Y Dong JB Wu MP 2008Eur J Pharmacol2008,590,:1
返回顶部 每页显示:
共25页 首页 上一页 第1页 下一页 末页 /25 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费